SALTO-2
SALTO -2 ( Long Term Monitoring In Oncology ) : Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes, Multicentric Study
Sponsor study identifier
Secondary identifiers
OTHER · ANSM
observational
137
1 country
4
Study Start
October 23, 2015
Actual (reported)Primary Completion
March 1, 2018
Actual (reported)Study Completion
March 1, 2018
Actual (reported)Children cancers are rare and survival rate are around 75%. 1 French adult out of 850 is estimated as a children-cancer-survivor. Chemotherapy, radiotherapy or surgical complications can lead to a late risk of death. A regularly support, a therapeutic education, a support of the psychological difficulties have a positive impact on the quality of life and on long-term health for patients surviving to a cancer. The ARCERRA exists, registering around 150 new cases a year. They coordinated, from 2011 to 2014, a multicentric study with a long term follow up in oncology (SALTO). 150 patients diagnosed between 1987 and 1992 were included, and the study demonstrated the feasibility and utility for patients and their physicians of a long-term follow-up coupled with an interview with a psychologist in Rhône-Alpes-Auvergne. The primary objective of SALTO-2 project is to know the becoming of young adults that survived to pediatric cancer, diagnosed in Rhône-Alpes between 1993 and 1999. The second objective is in one hand to study the psychological becoming and on another hand, to ameliorate their lifestyle thanks to different documents created specially for them.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2018
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 23, 2015
Actual (reported)January 22, 2016
Actual (reported)February 5, 2016
Actual (reported)March 1, 2018
Actual (reported)March 1, 2018
Actual (reported)Medical complications (post cancer treatment)
The investigators note the medical complications from the end of their cancer treatment to the inclusion visit. Theses complications depend on the type of treatment received.
15 years after the end of the cancer treatment
MINI questionnaire score
15 years after the end of the cancer treatment
MINI questionnaire score
17 years after the end of the cancer treatment
544 patients alive and that are min 18 years old, included in the ARCERRA population register, for a primary cancer (not leukemia), diagnosed between 15 years old, between January the 1st 1993, and December the 31st 1999, in Rhône-Alpes.
Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The study population is composed of 544 patients registered in the ARCERRA documùent. They survived at a pediatric cancer, diagnosed in Rhône-Alpes between January the 1st 1993 and December the 31st 1999. They were less than 15 years old during this period.
Chu Grenoble
Grenoble, 38000, France
IHOP1 de Lyon
Lyon, 69000, France
CH Lyon Sud - Pierre Bénite
Lyon, France
Chu Saint Etienne
Saint-Etienne, 42100, France
Tardy F, Casagranda L, Protiere A, Buisson-Papet G, Garcin A, Trombert-Paviot B, Freycon C, Marec-Berard P, Massoubre C, Berger C. Long-Term Clinical and Psychiatric Complications of Young Adults Cured of a Pediatric Bone Tumor Diagnosed Between 1987 and 1999 in Rhone: Alpes Region (France). J Adolesc Young Adult Oncol. 2022 Dec;11(6):571-579. doi: 10.1089/jayao.2021.0145. Epub 2022 Jan 18.
BERGER Claire, MD
Centre Hospitalier Universitaire de Saint Etienne
Léonie CASAGRANDA, PhD
Centre Hospitalier Universitaire de Saint Etienne
137 participants (actual enrollment reported by the registry).
First Submitted
January 22, 2016
First Posted
February 5, 2016
Study Start
October 23, 2015
Actual (reported)Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors
Quality of life : SF-36 scale
15 years after the end of the cancer treatment
Quality of life : SF-36 scale
17 years after the end of the cancer treatment
Contact the study team to confirm eligibility.
Primary Completion
March 1, 2018
Actual (reported)Study Completion
March 1, 2018
Actual (reported)Last Updated
October 22, 2018
Record last verified: 2018-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: